Scholar Rock is a single-asset biotech whose investment case rests entirely on the commercial trajectory of apitegromab; elevated short interest of 17% and consecutive earnings misses signal the market harbors deep skepticism that the company can reach profitability.
Thesis pillars
- Analyst Upside Valuation Buffer↓Deteriorating
- Apitegromab Pipeline Concentration↓Deteriorating
- Earnings Miss Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 3, 2026· older than 90 days
Scholar Rock Holding Corporatio (SRRK) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $43.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 2.10; Below-average business quality.
Scholar Rock is a clinical-stage biopharmaceutical company developing apitegromab, a selective anti-myostatin antibody for spinal muscular atrophy, with positive Phase 3 SAPPHIRE data reported in October 2024. The company has no approved products; its BLA received a Complete... Read more
Sell if holding. Engine safety override at $43.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 2.10; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Score 5.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: speculative.
About Scholar Rock Holding Corporatio
About Scholar Rock Holding Corporatio
Scholar Rock's lead candidate, apitegromab—the first selective latent myostatin inhibitor to achieve a statistically significant Phase 3 outcome in spinal muscular atrophy—reported positive SAPPHIRE trial results in October 2024. The company submitted a BLA to the FDA in January 2025 and a marketing authorization application to the EMA in March 2025. Scholar Rock received a Complete Response Letter from the FDA in September 2025 citing GMP deficiencies at a third-party fill-finish facility, delaying the anticipated U.S. commercial launch.
Scholar Rock plans to commercialize apitegromab for SMA, subject to regulatory approval, targeting initial launches in the U.S. and Europe beginning with Germany, supported by a U.S. customer-facing team of approximately 50 neurology and rare disease professionals established during 2025. An estimated 35,000 SMA patients globally have received an approved SMN-targeted treatment, defining the initial addressable market for apitegromab as a muscle-targeted complement. The company relies on a third-party fill-finish facility for apitegromab commercial manufacturing—the same facility that received an FDA Form 483 in July 2025 and an FDA warning letter in November 2025, with an OAI inspection classification that prompted the BLA's CRL. A subcutaneous formulation of apitegromab completed a Phase 1 healthy volunteer study; further development activities are ongoing. SRK-439, a subcutaneously administered anti-myostatin antibody in Phase 1, has topline data expected in the second half of 2026.
Show full overview
Apitegromab's path to U.S. approval depends on resolution of GMP deficiencies at the third-party fill-finish facility that received an OAI inspection classification and an FDA warning letter in November 2025. Scholar Rock completed a Type A meeting with the FDA in November 2025, but the 10-K notes no BLA resubmission can proceed until the facility resolves the cited deficiencies. The EMA's MAA review may also be affected, given the agency's mutual recognition agreement with the FDA, and the 10-K notes persistent non-compliance could, in the most adverse scenario, result in a negative CHMP opinion from the European Commission.
See also: Healthcare · Biotechnology
From Scholar Rock Holding Corporatio's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Scholar Rock Holding Corporatio
Latest news
- NEWS Scholar Rock to Present at Upcoming Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Scholar Rock Holding Insider Purchases $12 Million in Company Shares — fiscal.ai Oct 28, 2026 positive
- NEWS Scholar Rock Receives FDA's Priority Review Voucher For Isembyld — benzinga Oct 23, 2026 positive
- NEWS Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 — fiscal.ai Oct 20, 2026
- NEWS Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spin — benzinga Oct 8, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-04T11:59:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineapitegromab10-K Item 1: 'Positive data from the successful Phase 3 SAPPHIRE study evaluating apitegromab in children and adults with SMA were reported in October 2024'
- HIGHSupplierthird-party fill-finish facility10-K Item 1A: 'we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $43.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 23%; Elevated put/call ratio: 2.10; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 69. Prior stop was $40.90. Score 5.1/10, moderate confidence.
Analyst target: $63.39 (+44.1% upside). Prior stop was $40.90. Stop-loss: $40.90.
Concentration risk — Pipeline: apitegromab; Concentration risk — Supplier: third-party fill-finish facility; Quality below floor (1.4 < 4.0).
Scholar Rock Holding Corporatio trades at a P/E of N/A (forward -17.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts rate SRRK, with a consensus score of 4.3/5. 16 analysts publish price targets averaging $70.
What does Scholar Rock Holding Corporatio do?Scholar Rock is a clinical-stage biopharmaceutical company developing apitegromab, a selective anti-myostatin antibody...
Scholar Rock is a clinical-stage biopharmaceutical company developing apitegromab, a selective anti-myostatin antibody for spinal muscular atrophy, with positive Phase 3 SAPPHIRE data reported in October 2024. The company has no approved products; its BLA received a Complete Response Letter from the FDA in September 2025 due to GMP deficiencies at a third-party fill-finish facility.